Faculty & Staff

Joan Garrett

Education/Credentials
  • BA: Ohio University
  • BS: Ohio University
  • PhD: Ohio State University

Contact Information

Peer Reviewed Publications

Display All

Hanker, A.B.,* Garrett, J.T.,* Estrada, M.V., Moore, P., Langley, E., Singh, S., Kim, P., Frampton, G., Sanford, E., Owens, P., Becker J., Groseclose, M., Castellino, S., Joensuu, H., Huober, J., Blase, J., Majjaj, S., Brohee, S., Venet, D., Brown, D., Baselga, J., Piccart, M., Sotiriou, C., Arteaga, C.L. 2017. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2 , ,

Schwarz, L., Fox, E., Balko, J., Garrett, J., Kuba, M., Estrada, M. V., Gonzalez-Angulo, A., Mills, G., Brewer, M.R., Mayer, I., Abramson, V., Rizzo, M., Kelley, M., Meszoely, I., Arteaga, C. L. 2014. D189Y LYN mutation mediates antiestrogen resistance in ER+ breast cancer. Journal of Clinical Investigation, 124 , 5490

Garner, A.P., Bialucha, C.U., Sprague, E.R., Garrett, J.T., Sheng, Q, Li, S., Sineshchekova, O., Saxena, P., Sutton, C.R., Chen, D., Chen, Y., Wang, H., Liang, J., Das, R., Mosher, R., Haubst, N., Zehetmeier, C., Haberl, M., Kunz, C., Elis, W., Heidt, A.B., Herlihy, K, Murtie, J., Arteaga, C.L., Sellers, W.R., Ettenberg, S.A. 2013. LJM716, an anti-HER3 antibody that locks HER3 in the inactive conformation and inhibits both HER2 and neuregulin driven tumor growth. Cancer Research, 73 , 6024

Garrett, J.T., Sutton, C.R., Kuba, M.G., Cook, R.S., Arteaga, C.L. 2013. Dual blockade of HER2 in HER2-overexpressing tumor cells does not eliminate HER3 function. Clin Cancer Res, 19 , 610

Garrett, J.T., Sutton, C.R., Kurupi, R., Bialucha, C.U., Ettenberg, S.A., Collins, S.D., Sheng, Q., Wallweber, J., DeFazio-Eli, L., Arteaga, C.L. 2013. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2-overexpressing breast cancers. Cancer Research, 73 , 6013

Cook, R.S., Garrett, J.T., Sánchez, V.K., Stanford, J.C., Young, C., Chakrabarty, A., Rinehart, C., Zhang, Y., Wu, Y., Greenberger, L., Horak, I.D., Arteaga, C.L. 2011. ErbB3 ablation impairs phosphatidylinositol 3-kinase (PI3K)/AKT-dependent mammary tumorigenesis Cancer Research, 71 , 3941

Garrett, J.T., and Arteaga, C.L. 2011. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications. Cancer Biol Ther , 11, 793

Garrett, J.T., Chakrabarty A, Arteaga, C.L. 2011. Will PI3K pathway inhibitors be effective as single agents in patients with cancer? Oncotarget, 2 , 1314

Garrett, J.T., Olivares, M.G., Rinehart, C., Granja-Ingram, N.M., Sánchez, V., Chakrabarty, A., Dave, B., Cook, R.S., Pao, W., McKinely, E.T., H. Manning, H.C., Chang, J.C., Arteaga, C.L. 2011. Transcriptional and post-translational upregulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A, 108 , 5021

Miller T.W., Rexer B.N., Garrett J.T., Arteaga CL. 2011. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. , 13, 224

Kaumaya, P.T., Foy, K.C., Garrett, J., Rawale, S.V., Vicari, D., Thurmond, J.M., Lamb, T., Mani, A., Kane, Y., Balint, C.R., Chalupa, D., Otterson, G. A., Shapiro, C.L., Fowler, J.M., Grever, M.R., Bekaii-Saab, T.S., Carson, W.E. 2009. Phase I Active Immunotherapy with Combination of Two Chimeric HER-2 B-cell Epitope Fused to a Promiscuous T-cell Epitope Emulsified with n-MDP Adjuvant and ISA 720 Vehicle in Patients with Metastatic and/or Recurrent Solid Tumors. J Clin Oncol., 27 , 5270

Allen, S.D.*, Garrett, J.T.*, Rawale, S., Jones, A.L., Phillips, G., Forni, G., Morris, J.C., Oshima, R.G., and Kaumaya, P.T. 2007. Peptide Vaccines of the HER-2/neu Dimerization Loop are Effective in Inhibiting Mammary Tumor Growth in vivo. J Immunol, 179 , 472

Garrett, J.T., Rawale, S., Allen, S.D., Phillips, G., Forni, G., Morris, J.C., and Kaumaya, P.T. 2007. Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu. J Immunol, 178 , 7120

Dakappagari, N.K., Lute, K.D., Rawale, S., Steele, J.T., Allen, S.D., Phillips, G., Reilly, R.T., and Kaumaya, P.T. 2005. Conformational HER-2/neu B-cell Epitope Peptide Vaccine Designed to Incorporate Two Native Disulfide Bonds Enhances Tumor Cell Binding and Antitumor Activities. J Biol Chem, 280 , 54

Visit the College

Group Photo of the dean and students

See our difference at the James L Winkle College of Pharmacy. We are among the oldest in the nation, with cutting-edge research, excellent scholarship and distinguished faculty. Visit the College to Learn More

Life in Cincinnati

Resting along the banks of the Ohio River, Cincinnati offers something for everyone. From foodies to sports fans, cultural hotspots to family-friendly attractions discover our dynamic city. Learn More about Life in Cincinnati

Photo of a statue